# Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

> **NCT02268435** · PHASE1 · WITHDRAWN · sponsor: **Asan Medical Center**

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** dovitinib plus imatinib

## Key facts

- **NCT ID:** NCT02268435
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Dovitinib Production stopped
- **Last updated:** 2015-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268435, "Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02268435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*